Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna, Inc. (Nasdaq: MRNA) announced a revised supply agreement with the Government of Canada for up to 105 million doses of its COVID-19 vaccine through 2024. The agreement stipulates 20 million doses in 2022 and 2023, with an option for an additional 15 million doses each year. For 2024, it allows for up to 35 million doses. Moderna's CEO, Stéphane Bancel, commended the Canadian government's support. This agreement further illustrates Moderna's role in combating the pandemic and highlights the company's ongoing collaboration with governmental partners.
Moderna (Nasdaq: MRNA) has commenced a Phase 1/2 trial for mRNA-3705, an investigational therapy targeting methylmalonic acidemia (MMA) caused by MUT deficiency. The first patient has been enrolled in the study assessing the safety and tolerability of this mRNA therapeutic. MMA is a rare metabolic disorder with no approved treatments, and current options are limited to dietary management and transplants. mRNA-3705 aims to restore missing enzymes to improve patient outcomes. The FDA has granted it Orphan Drug and Rare Pediatric Disease designations.
Moderna, Inc. (Nasdaq: MRNA) announced FDA approval for a third dose of its COVID-19 vaccine (mRNA-1273) for immunocompromised individuals 18 and older. This decision is based on recent studies indicating enhanced immune responses in this population. The vaccine has previously received emergency use authorization and is actively utilized across over 50 countries. Moderna's CEO emphasized the commitment to improving protection against COVID-19, particularly for those at higher risk. The company continues to research the vaccine's effectiveness against variants.
Moderna, Inc. (Nasdaq:MRNA) announced new findings regarding the effectiveness of its COVID-19 vaccine, demonstrating durable neutralizing antibodies against several variants, including Delta, for up to six months post-vaccination. The study highlights that 93% efficacy is maintained over this period, with most participants retaining detectable antibody levels. While a slight decrease in antibody levels was noted, especially in older individuals, many preserved their neutralizing activity. This data aims to inform health regulators about potential booster doses.
Moderna (Nasdaq: MRNA) has signed a Memorandum of Understanding with the Canadian government to establish a new mRNA vaccine manufacturing facility in Canada. This facility aims to enhance Canada's pandemic response capabilities and provide access to Moderna's vaccines for respiratory viruses, including COVID-19. CEO Stéphane Bancel emphasized the collaboration's significance in global public health, stating the company's commitment to leveraging mRNA technology. The partnership is expected to foster Moderna's presence in Canada and further develop its mRNA portfolio.
Moderna (Nasdaq: MRNA) has received provisional registration from Australia’s Therapeutic Goods Administration for its COVID-19 Vaccine, authorized for individuals aged 18 and over. Vaccine delivery is set to begin in September 2021. The Australian government secured 10 million doses for 2021 with an option for an additional 15 million in 2022. Aside from Australia, Moderna has received approvals from over 50 countries and the WHO for its vaccine. Ongoing evaluations for adolescent use are underway, highlighting the vaccine's broad acceptance and demand.
Summary not available.
Moderna (Nasdaq: MRNA) reported Q2 2021 financial results with total revenue of $4.4 billion, a significant increase from $67 million in Q2 2020, driven primarily by COVID-19 vaccine sales. The company expects dose capacity to range from 800 million to 1 billion doses in FY 2021. Moderna's COVID-19 vaccine shows a durable efficacy of 93% over six months. The company is advancing multiple mRNA candidates across therapeutic areas, including upcoming Phase 3 trials for RSV and flu vaccines, and has received Fast Track designation for its RSV vaccine.
Moderna (Nasdaq: MRNA) announced that the FDA has granted Fast Track designation for its investigational mRNA-1345, a single-dose vaccine against respiratory syncytial virus (RSV) targeting adults over 60. The vaccine aims to protect vulnerable populations, such as older adults and young children, as RSV leads to significant hospitalizations and deaths annually. Moderna is conducting ongoing clinical trials for mRNA-1345 and plans to assess its combinations with other vaccines. The company has previously received Fast Track designations for several other vaccine candidates.
Moderna (Nasdaq: MRNA) has dosed its first participant in the Phase 1 study of mRNA-6231, its first autoimmune candidate designed to expand regulatory T cells. This marks a significant milestone as it is also the company's first subcutaneously administered therapeutic. The trial aims to evaluate the safety and tolerability of mRNA-6231 in healthy adults. Moderna continues to advance its mRNA platform with programs in various therapeutic areas, highlighting its commitment to addressing autoimmune diseases.